• 1
    Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87: 158692.
  • 2
    Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85: 2316.
  • 3
    Hochberg MC, Ross PD, Black D et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 1999; 42: 124654.
  • 4
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18: 10516.
  • 5
    Liberman UA, Weiss SR, Broll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 143743.
  • 6
    Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693700.
  • 7
    Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996; 101: 488501.
  • 8
    Tonino RP, Meunier PJ, Emkey R et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000; 85: 310915.
  • 9
    Cranney A, Wells G, Willan A et al. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23: 50816.
  • 10
    Häuselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 2003; 14: 212.
  • 11
    Levis S, Quandt SA, Thompson D et al. Alendronate reduces the risk of multiple symptomatic fractures: results from the Fracture Intervention Trial. J Am Geriatr Soc 2002; 50: 40915.
  • 12
    Pols HAP, Felsenberg D, Hanley DA et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999; 9: 4618.
  • 13
    Black DM, Thompson DE, Bauer DC et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000; 85: 411824.
  • 14
    Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999; 282: 63745.
  • 15
    Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001; 12: 92230.
  • 16
    Cranney A, Tugwell P, Zytaruk N et al. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal women. Endocr Rev 2002; 23: 5248.
  • 17
    Riggs BL, Hartmann LC. Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N Engl J Med 2003; 348: 61829.
  • 18
    Cranney A, Guyatt G, Griffith L et al. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 5708.
  • 19
    Kanis JA, Oden A, Johnell O et al. Uncertain future of trials in osteoporosis. Osteoporos Int 2002; 13: 4439.
  • 20
    Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996; 11: 33749.
  • 21
    Johnell O, Scheele WH, Lu Y, Reginster J-Y, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 98592.
  • 22
    Khosla S. Surrogates for fracture endpoints in clinical trials. J Bone Miner Res 2003; 18: 11469.
  • 23
    Lafage MH, Balena R, Battle MA et al.. Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one year study. J Clin Invest 1995; 95: 12733.
  • 24
    Lees CJ, Register TC, Turner CH, Wang T, Stancill M, Jerome CP. Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys. Menopause 2002; 9: 3208.
  • 25
    Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002; 17: 110.
  • 26
    Cummings SR, Palermo L, Browner W et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 2000; 283: 131821.